These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20703925)

  • 1. Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events.
    Ohashi W; Tanaka H
    J Med Syst; 2010 Aug; 34(4):701-7. PubMed ID: 20703925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will there be a role for genotyping in warfarin therapy?
    Gandara E; Wells PS
    Curr Opin Hematol; 2010 Sep; 17(5):439-43. PubMed ID: 20601874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation of pharmacogenetics into clinically relevant testing modalities.
    Baudhuin LM; Langman LJ; O'Kane DJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):373-6. PubMed ID: 17851577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
    Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
    Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of warfarin pharmacogenetic testing in clinical practice.
    Tan GM; Wu E; Lam YY; Yan BP
    Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacogenomics of warfarin (Coumadin) administration.
    Ruano G; Bower B
    Conn Med; 2006 Apr; 70(4):251-2. PubMed ID: 16768072
    [No Abstract]   [Full Text] [Related]  

  • 8. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
    Krynetskiy E; McDonnell P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.
    Rosove MH; Grody WW
    Ann Intern Med; 2009 Aug; 151(4):270-3, W95. PubMed ID: 19687493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
    Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
    Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Companion Diagnostics for Thrombotic Disease].
    Masuda Y; Matsuno K; Shimizu C
    Rinsho Byori; 2015 Nov; 63(11):1316-22. PubMed ID: 26995878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic influences on the response to warfarin.
    Kamali F
    Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 16. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.
    Shah SN; Gammal RS; Amato MG; Alobaidly M; Reyes DD; Hasan S; Seger DL; Krier JB; Bates DW
    Drug Saf; 2021 May; 44(5):601-607. PubMed ID: 33620701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.
    Pratt VM; Cavallari LH; Del Tredici AL; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; Whirl-Carrillo M; Weck KE
    J Mol Diagn; 2020 Jul; 22(7):847-859. PubMed ID: 32380173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.
    Martes-Martinez C; Méndez-Sepúlveda C; Millán-Molina J; French-Kim M; Marín-Centeno H; Rivera-Miranda GC; Hernández-Muñoz JJ; Duconge-Soler J
    P R Health Sci J; 2017 Sep; 36(3):165-172. PubMed ID: 28915306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
    Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
    Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.